Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTA vs OCALIVA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist. FXR is a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces the production of bile acids by suppressing cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis, and increases the expression of FXR target genes involved in bile acid transport and detoxification.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
5 mg orally once daily, increase to 10 mg once daily if adequate response after 3 months.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
The terminal elimination half-life of obeticholic acid is approximately 24 hours for the parent drug and 3.5 to 5.8 days for its active conjugates (glyco- and tauro-obeticholic acid). This long half-life supports once-daily dosing but indicates that steady-state is reached after about 2 weeks.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Obeticholic acid is metabolized in the liver and intestine via conjugation with glycine or taurine, and subsequently undergoes extensive enterohepatic recirculation. It is not significantly metabolized by CYP450 enzymes. The conjugated metabolites are eliminated in feces.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Following oral administration, approximately 87% of the dose is excreted in feces (primarily as unchanged drug and metabolites) and less than 3% is excreted renally. Biliary excretion is the major route for the parent drug and its conjugates.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Obeticholic acid is approximately 99% bound to plasma proteins, primarily albumin.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
The volume of distribution is approximately 6.5 L/kg, indicating extensive extravascular distribution, consistent with its lipophilic nature and high tissue binding, particularly to liver and intestinal tissues.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Absolute bioavailability of oral obeticholic acid is approximately 50%, with a range of 30-70% due to first-pass hepatic metabolism and conjugation.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m2).
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Child-Pugh class A: No adjustment. Child-Pugh class B: Initial dose 5 mg once daily, increase to 10 mg if tolerated. Child-Pugh class C: Contraindicated.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Safety and efficacy not established in pediatric patients.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
No specific dose adjustment; use caution due to potential for increased exposure and hepatic impairment.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
WARNING: HEPATIC DECOMPENSATION AND LIVER FAILURE IN INCORRECTLY DOSED PBC PATIENTS WITH CHILD-PUGH CLASS B OR DECOMPENSATED CIRRHOSIS. Patients with Child-Pugh class B or decompensated cirrhosis (Child-Pugh class C) are at increased risk of hepatic decompensation and liver failure when incorrectly dosed. Ocaliva is contraindicated in patients with decompensated cirrhosis (Child-Pugh class C). In patients with Child-Pugh class B, the starting dose is 5 mg once weekly, with dose adjustment based on response and tolerability.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hepatic decompensation and liver failure in patients with Child-Pugh class B or decompensated cirrhosis,Risk of hepatic decompensation in patients with moderate to severe hepatic impairment,Severe pruritus: dose reduction, antihistamines, or bile acid resins may be considered,Reduction in HDL-C levels; monitor lipid levels periodically,Monitor liver function tests (e.g., bilirubin, INR) and signs of hepatic decompensation
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Complete biliary obstruction,Decompensated cirrhosis (Child-Pugh class C),Known hypersensitivity to obeticholic acid or any component of the formulation
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
No specific food restrictions; however, consistent administration with or without food is recommended. Avoid grapefruit juice as it may increase drug exposure. Limit alcohol consumption to reduce liver stress.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
There are no adequate and well-controlled studies of Ocaliva in pregnant women. In animal reproduction studies, oral administration of obeticholic acid to pregnant rats and rabbits during organogenesis at doses less than the maximum recommended human dose (MRHD) resulted in embryofetal mortality and malformations. Based on animal data, Ocaliva may cause fetal harm when administered to a pregnant woman. Avoid use during pregnancy, especially in the first trimester, unless the potential benefit to the mother outweighs the potential risk to the fetus.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
It is not known whether obeticholic acid is excreted in human milk. In animal studies, obeticholic acid and/or its metabolites were detected in milk of lactating rats. The M/P ratio is not available. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Ocaliva, women should not breastfeed during treatment and for 3 weeks after the last dose.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
No specific dose adjustments for pregnancy are provided in the labeling. Ocaliva is contraindicated in patients with complete biliary obstruction, and use during pregnancy should be avoided. If use is essential, no data exist to guide dose modifications; pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may necessitate empiric dose adjustment, but no formal studies have been conducted.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
OCALIVA (obeticholic acid) is a farnesoid X receptor agonist for primary biliary cholangitis (PBC). Monitor liver function tests closely; dose adjustments needed in moderate to severe hepatic impairment (Child-Pugh B or C). Titrate from 5 mg to 10 mg based on tolerability after 3 months. Contraindicated in patients with complete biliary obstruction. Pruritus is common; consider antihistamines or bile acid binders. Check INR if on warfarin due to potential interaction.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
Take with or without food, but be consistent with meals to maintain stable drug levels.,Do not stop or change dose without consulting your healthcare provider.,Report severe itching, jaundice, or dark urine immediately.,Avoid alcohol and medications that can harm the liver.,Inform all healthcare providers you are taking this medication.,Attend regular blood tests to monitor liver function and treatment response.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTA vs OCALIVA, answered by our medical review team.
ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. OCALIVA is a Farnesoid X receptor agonist that works by Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist. FXR is a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces the production of bile acids by suppressing cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis, and increases the expression of FXR target genes involved in bile acid transport and detoxification.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTA and OCALIVA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. The standard adult dose of OCALIVA is: 5 mg orally once daily, increase to 10 mg once daily if adequate response after 3 months.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTA and OCALIVA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. OCALIVA is classified as Category C. There are no adequate and well-controlled studies of Ocaliva in pregnant women. In animal reproduction studies, oral administration of obeticholic acid to pregnant rats and rabbits. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.